COMPANY PROFILE

NA Vaccine

Explore full profile

Potentiated vaccines for global immunization ensuring no child is left without protection

Seoul, South KoreaFounded 2018Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Total funding $10–50M Disclosed equity funding

Unlock exact values

About NA Vaccine

NA Vaccine Institute is dedicated to enhancing global immunization through the development of potentiated vaccines. Operating in the healthcare and biotechnology sector, the company focuses on creating advanced vaccines that provide stronger and longer-lasting immunity. Their primary clients include governments, international health organizations, and healthcare providers. NA Vaccine Institute's business model revolves around research and development, followed by the production and distribution of these vaccines. Revenue is generated through government contracts, partnerships with global health organizations, and direct sales to healthcare providers. The company is headquartered in Seoul, Korea, and aims to ensure that no child is left without a vaccine, contributing to global health security.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Seoul, South Korea
Open positions: None listed
Dealroom signal: 17.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Nov 2021	$13M	$52M	Undisclosed	—
OtherOther financing	Jan 2020	$0	—	IMM Investment	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

NA Vaccine website traffic

Latest recorded traffic for NA Vaccine is 5.7K monthly website visits, up 7.5% over the last three months.

Latest monthly visits5.7K 3-month web change+7.5%

Monthly website visitsApr 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
ATAlia TherapeuticsMolecular components for genetic editing to address rare diseases	Pergine Valsugana, Italy	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational
CSCANbridge Life SciencesBio-pharmaceutical company accelerating development and commercialization of specialty healthcare	Cambridge, United States	Operational
AZAzafarosDevelops new therapeutic agents for the treatment of rare metabolic disorders	Leiden, Netherlands	Operational
CPCensa PharmaceuticalsDevelopment and commercialization of therapeutics for (ultra) orphan cns disorders	Cambridge, United States	Acquired
XPX4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment	Cambridge, United States	Operational
CPCerium PharmaceuticalsEmerging biopharmaceutical company dedicated to the development and commercialization of medicines	Gaithersburg, United States	Operational